Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$59.02 USD
-0.95 (-1.58%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $59.00 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Fundamental Charts
About Dividend Yield (TTM)
Halozyme Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
HALO 59.02 -0.95(-1.58%)
Will HALO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HALO
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
Other News for HALO
Fidelity Small Cap Index Fund Q2 2025 Commentary
Fidelity Small Cap Growth Fund Q2 2025 Commentary
J&J says Darzalex injectable granted EU nod for smouldering multiple myeloma
Halozyme says EU approves new indication for Janssen's Darzalex Faspro